2024 年年度股东大会的 法律意见 北京德恒（杭州）律师事务所 关于浙江海森药业股份有限公司 关于浙江海森药业股份有限公司 2024年年度股东大会的 法律意见 致：浙江海森药业股份有限公司 北京德恒（杭州）律师事务所受浙江海森药业股份有限公司（以下简称"海 森药业"或"公司"）委托，指派黄君福律师、王子安律师（以下简称"本所律 师"）出席公司 2024 年年度股东大会（以下简称"本次股东大会"），并对本 次股东大会的合法性进行见证并出具法律意见。 本法律意见根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》， 以及《浙江海森药业股份有限公司章程》（以下简称"《公司章程》"）等有关 法律、法规和规范性文件而出具。 杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 邮编：310016 电话：(+86)0571-86508080 传真：(+86)0571-87357755 北京德恒（杭州）律师事务所 关于浙江海森药业股份有限公司 2024 年年度股东大会的法律意见 北京德恒（杭州）律师事务所 为出具本法律意见，本所律师审 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.3100 | 0.3300 | -6.06 | 0.4900 | | 每股净资产（元） | 13.45 | 18.87 | -28.72 | 9.69 | | 每股公积金(元) | 7.45 | 11.22 | -33.6 | 2.05 | | 每股未分配利润(元) | 4.70 | 6.01 | -21.8 | 5.80 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.18 | 1.16 | 1.72 | 1.07 | | 净利润(亿元) | 0.31 | 0.33 | -6.06 | 0.25 | | 净资产收益率(%) | 2.29 | 2.64 | -13.26 | 5.19 | 数据四舍五入，查看更多财务数据>> | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | - ...

Financial Performance - The company's revenue for Q1 2025 was ¥118,478,458.16, representing a 2.32% increase compared to ¥115,797,089.07 in the same period last year[5] - Net profit attributable to shareholders decreased by 6.51% to ¥31,212,181.59 from ¥33,384,770.13 year-on-year[5] - Basic earnings per share decreased by 6.06% to ¥0.31 from ¥0.33 in the same period last year[5] - Total operating revenue for the current period reached ¥118,478,458.16, an increase of 2.93% compared to ¥115,797,089.07 in the previous period[21] - Net profit for the current period was ¥31,212,181.59, a decrease of 6.5% from ¥33,384,770.13 in the previous period[22] - Earnings per share (basic) decreased to 0.31 from 0.33, indicating a decline of 6.06%[23] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 87.47%, reaching ¥40,458,787.37 compared to ¥21,581,743.55 in the previous year[5] - Operating cash flow for the current period was CNY 40,458,787.37, a significant increase of 87.6% compared to CNY 21,581,743.55 in the previous period[25] - Total cash inflow from operating activities reached CNY 104,381,799.72, up from CNY 87,021,728.05, reflecting a growth of 19.9%[25] - Cash and cash equivalents at the end of the period totaled CNY 859,080,388.92, down from CNY 944,815,526.11, indicating a decrease of 9.1%[25] - The company reported a net decrease in cash and cash equivalents of CNY 175,401,723.36 for the current period, contrasting with an increase of CNY 8,027,047.49 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,505,934,094.12, a 1.34% increase from ¥1,485,991,744.60 at the end of the previous year[5] - Total liabilities decreased to ¥125,389,912.30 from ¥141,837,087.40, a reduction of 11.6%[19] - The total equity attributable to shareholders increased to ¥1,380,544,181.82 from ¥1,344,154,657.20, reflecting a growth of 2.7%[19] Research and Development - Research and development expenses surged by 120.63% to ¥9,441,180.96, up from ¥4,279,248.99 in the previous year, primarily due to increased employee compensation and external research[9] - Research and development expenses rose significantly to ¥9,441,180.96, compared to ¥4,279,248.99, marking an increase of 107.5%[22] - The company has extended the expected completion date of the R&D center project from March 31, 2025, to September 30, 2025[15] Investments and Projects - The company signed an investment cooperation agreement with the Dongyang Economic Development Zone Management Committee to invest at least RMB 2 billion in the construction of a new pharmaceutical plant[12] - The project for the production line of 200 tons of Atorvastatin Calcium has been changed to a new project with a capacity of 300 tons, responding to market demand[14] - The company has adjusted its fundraising project to prioritize the construction of leading raw material drug production lines to meet growing market needs[14] - The company is actively promoting the construction of the new plant project and will comply with relevant laws and regulations for timely information disclosure[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,872, with the largest shareholder, Zhejiang Haisen Holdings, holding 32.31% of the shares[10] - The company will hold a temporary shareholders' meeting on March 7, 2025, to review the investment cooperation agreement and project updates[12] Other Financial Metrics - Total operating costs amounted to ¥83,568,452.19, up from ¥77,405,038.60, reflecting a rise of 8.3%[21] - The company reported a financial expense of -¥2,554,692.80, an improvement from -¥5,063,404.17 in the previous period[22] - The company experienced a 49.46% increase in selling expenses, totaling ¥2,561,780.56, attributed to higher employee compensation and stock incentives[9] - The company reported a significant increase in investment income, which rose to ¥213,663.34, marking a 100% increase due to higher returns from financial investments[9] - The company reported a 724.29% increase in non-operating income, amounting to ¥501,168.49, primarily due to increased government subsidies unrelated to daily operations[9] Audit Status - The first quarter report was not audited, indicating that the financial data may be subject to further review[27]

Group 1: Financial Performance - The company achieved a revenue of 471.51 million yuan in 2024, representing an 18.63% increase compared to the previous year [2] - The sales growth for the main business segments was 16.74% for raw materials, 35.51% for intermediates, and 45.82% for formulations [2] - The cash balance at the end of the reporting period was 1.03 billion yuan, indicating sufficient cash flow [4] Group 2: Strategic Initiatives - The company plans to extend its industrial chain by enhancing R&D innovation and product quality, aiming for a full industrial chain layout from raw materials to formulations [3] - The new investment project has been changed to a "300 tons/year A-40 (Atorvastatin Calcium) specialty raw material project," with a total investment of 414.39 million yuan, expected to be operational by December 31, 2027 [4] - R&D investment increased by 47.44% in 2024, with a focus on developing 17 ongoing projects related to antiviral, antidepressant, lipid-lowering, anti-inflammatory, anti-rheumatic, and anti-ulcer medications [8] Group 3: Market Expansion - The company has a significant portion of revenue from international markets, with major export regions including Asia, Europe, and America [3] - In 2024, overseas revenue accounted for 50% of total revenue, with a small proportion coming from direct exports to the U.S. [7] - The company is actively working to expand its market presence in the U.S. and other regions, despite limited impact from U.S. tariff policies [8] Group 4: Corporate Governance and Investor Relations - The company emphasizes shareholder returns and plans to maintain a sustainable dividend policy based on operational performance and cash flow [4] - Measures are in place to protect the rights of minority investors, including transparent voting processes and communication channels [6] - The company has established a robust internal control system to ensure compliance with revenue recognition standards [9]

中信证券股份有限公司 关于浙江海森药业股份有限公司 2024 年度持续督导定期现场检查报告 （四）保护公司利益不受侵害长效机制的建立和执行情况 现场检查手段： 查阅公司章程及相关制度文件；查阅关联交易、对外担保、重大对外投资的明细， 查阅决策程序和信息披露材料，分析关联交易的定价公允性；查阅公司与控股股 东、实际控制人及其关联方的资金往来明细及相关内部审议文件、信息披露文件， 查阅发行人及其控股股东、实际控制人关于是否存在违规占用发行人资金的说 明，查阅会计师关于 2024 年度控股股东及其他关联方占用发行人资金情况的专 项报告，对财务总监、年审会计师进行了访谈。 | 1.是否建立了防止控股股东、实际控制人及其关联人直接 | √ | | --- | --- | | 或者间接占用上市公司资金或者其他资源的制度 | | | 2.控股股东、实际控制人及其关联人是否不存在直接或者 | √ | | 间接占用上市公司资金或者其他资源的情形 | | | 3.关联交易的审议程序是否合规且履行了相应的信息披露 | √ | | 义务 | | | | --- | --- | --- | | 4.关联交易价格是否公允 | √ | | ...

基于 2024年度现场检查,本保荐人提请贵公司关注以下事项: 1、建议公司继续按照《公司法》《证券法》《上市公司监管指引第2 号 -- 上市公司募集资金管理和使用的监管要求(2022年修订)》《深圳证券交易所股 票上市规则(2024年修订)》、《深圳证券交易所上市公司自律监管指引第1号 -- 主板上市公司规范运作(2023年12月修订)》等法律法规的要求,不断完善上 市公司治理结构,不断提高公司规范运作水平,强化风险防范意识,及时履行信 息披露义务,确保信息披露真实、准确、完整,做好避免上市公司利益受损的管 理工作。 中信证券股份有限公司 关于浙江海森药业股份有限公司2024年持续督导工作现场检查 结果及提请公司注意事项 浙江海森药业股份有限公司: 中信证券股份有限公司(以下简称"本保荐人")作为对贵公司进行持续督导 的保荐人,按照《深圳证券交易所上市公司自律监管指引第13号 -- 保荐业务》 (2025年修订)的有关要求,对贵公司认真履行了持续督导职责。 附件:《定期现场检查报告》 保荐人:中信证: 2、建议公司持续、合规合理安排募集资金使用,有序推进募投项目的建设 及实施,并按照募集资金管理和使用的相关规 ...

中信证券股份有限公司 关于浙江海森药业股份有限公司 2024年度保荐工作报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：海森药业 | | --- | --- | | 保荐代表人姓名：徐峰 | 联系电话：0571-85783757 | | 保荐代表人姓名：董超 | 联系电话：0571-85783715 | | | 资者关系管理、内部控制等 | | --- | --- | | 11.其他需要说明的保荐工作情况 | 无 | 二、保荐人发现公司存在的问题及采取的措施 | 事项 | 存在的问题 | | 采取的措施 | | --- | --- | --- | --- | | | 保荐人查阅了公司信息披露文件，投资者关 系登记表，深圳证券交易所互动易网站披露 信息管理和知情人登记管理情况，信息披露 | 不适用 | | | | 信息，重大信息的传递披露流程文件，内幕 | | | | 1.信息披 | | | | | 露 | 管理制度，会计师出具的2024年度内部控制 | | | | | 鉴证报告，检索公司舆情报道，对高级管理 | | | | | 人员进行访谈，未发现公司在信息披露方面 | | | | | 存在重 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 为充分尊重投资者、提升交流的针对性，现就公司2024年度业绩说明会提前向投资者公开征集问题，广 泛听取投资者的意见和建议。投资者可于2025年4月14日（星期一）15:00 前访问https://ir.p5w.net/zj/， 或扫描下方二维码，进入问题征集专题页面。公司将在2024年度业绩说明会上，对投资者普遍关注的问 题进行回答。 欢迎广大投资者积极参与本次业绩说明会。 ■ （问题征集专题页面二维码） 特此公告。 证券代码：001367 证券简称：海森药业 公告编号：2025-020 浙江海森药业股份有限公司 关于举行2024年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 浙江海森药业股份有限公司（以下简称"公司"）定于2025年4月15日（星期二）15:00-16:00在全景网举 办2024年度业绩说明会，本次业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关 系互动平台"（https://ir.p5w.net）或者直接进入公司路演厅（https://ir.p5w. ...

证券代码：001367 证券简称：海森药业 公告编号：2025-020 浙江海森药业股份有限公司 为充分尊重投资者、提升交流的针对性，现就公司2024年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2025年4月 14日（星期一）15:00 前访问https://ir.p5w.net/zj/，或扫描下方二维码，进入问题 征集专题页面。公司将在2024年度业绩说明会上，对投资者普遍关注的问题进行 回答。 欢迎广大投资者积极参与本次业绩说明会。 特此公告。 （问题征集专题页面二维码） 浙江海森药业股份有限公司董事会 2025 年 4 月 10 日 关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海森药业股份有限公司（以下简称"公司"）定于2025年4月15日（星 期二）15:00-16:00在全景网举办2024年度业绩说明会，本次业绩说明会将采用网 络远程的方式举行，投资者可登陆全景网"投资者关系互动平台"（https://ir.p5 w.net）或者直接进入公司路演厅（https: ...